Elevated Derived Neutrophil-to-Lymphocyte Ratio Corresponds With Poor Outcome in Patients Undergoing Pre-Operative Chemotherapy in Muscle-Invasive Bladder Cancer

Kim E.M. van Kessel(Erasmus University Rotterdam), Joost L. Boormans(Erasmus MC), Ellen C. Zwarthoff(Erasmus MC), Ronald de Wit(Erasmus MC Cancer Institute), Elisabeth E. Fransen van de Putte(The Netherlands Cancer Institute), Lorraine M. de Haan(Erasmus MC Cancer Institute), Bas W.G. van Rhijn(The Netherlands Cancer Institute), Michiel S. van der Heijden(Zorginstituut Nederland)
Bladder Cancer
July 11, 2016
10.3233/blc-160055
Cited by 30

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2017|1.4k
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2017|1.3k